论文部分内容阅读
将确诊的84例尘肺病患者随机分为2组:治疗组44例、对照组40例,治疗组在常规治疗的基础上加用胸腺五肽1 mg肌内注射,qd,15 d为一个疗程,共6个疗程;对照组给予常规治疗。结果显示,治疗组1个月、6个月血清免疫球蛋白指标高于治疗前,差异有统计学意义(P<0.05,P<0.01);亦高于对照组,差异有统计学意义(P<0.01);治疗组外周血T淋巴细胞亚群组的CD3~+、CD4~+指标高于治疗前和对照组,CD8~+低于治疗前和对照组,差异有统计学意义(P<0.05或P<0.01);治疗组1年内呼吸道感染发病次数较对照组明显降低,其显效率为81.8%,总有效率为93.1%。提示胸腺五肽能提高尘肺病患者免疫功能,减少呼吸道反复感染。
The 84 cases of pneumoconiosis diagnosed were randomly divided into two groups: the treatment group 44 cases, the control group 40 cases, the treatment group on the basis of conventional treatment with thymopentin 1 mg intramuscular injection, qd, 15 d for a course of treatment , A total of 6 courses; control group given conventional treatment. The results showed that the index of serum immunoglobulin at 1 month and 6 months in treatment group was significantly higher than that before treatment (P <0.05, P <0.01), and also higher than that in control group (P <0.01). The levels of CD3 ~ + and CD4 ~ + in peripheral blood T lymphocyte subsets in the treatment group were significantly higher than those before treatment and in the control group, while those in the control group and the CD8 ~ + group were lower than those before treatment (P < 0.05 or P <0.01). The incidence of respiratory tract infection in the treatment group was significantly lower than that in the control group within one year. The effective rate was 81.8% and the total effective rate was 93.1%. Tip thymopentin can improve immune function in patients with pneumoconiosis, reduce respiratory tract infection.